Brief: Harrow To Launch FDA-Approved Iheezo™ At The 2023 American Society Of Cataract And Refractive Surgery (Ascrs) Annual Meeting
04/05/2023 13:01
May 4 (Reuters) - Harrow Health Inc HROW.O :
* HARROW TO LAUNCH FDA-APPROVED IHEEZO™ AT THE 2023 AMERICAN
SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS) ANNUAL
MEETING
Source text for Eikon: ID:nBw4gPL78a
Further company coverage: HROW.O
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates